Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Suspended 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Thoracic 3Other solid neoplasm 1Gastrointestinal 1

Conditions

NSCLC 3

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × HM781-36B × Thoracic × Clear all
NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended
268 enrolled
Thoracic

NSCLC

NCT03318939 2024-04-03

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
648 enrolled
Thoracic

NSCLC

NCT04044170 2020-11-17

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Hanmi Pharmaceutical Company Limited

Phase 2 Terminated
5 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡